Literature DB >> 22119907

[Unclear hepatopathy in a patient with atrial fibrillation].

C Pennartz1, H Schrader, P R Ritter, A Tannapfel, W E Schmidt, J J Meier.   

Abstract

Although liver damage is a relatively rare adverse effect of oral anticoagulation with phenprocoumon, acute liver failure can be a serious treatment-associated complication. In this contribution, a patient with drug-induced liver failure during oral anticoagulation with phenprocoumon is presented. This case illustrates the need for close laboratory monitoring and suggests that phenrocoumon-induced liver damage should be considered along with other common complications of this treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22119907     DOI: 10.1007/s00108-011-2908-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  10 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  Subacute liver failure induced by phenprocoumon treatment.

Authors:  H Mix; S Wagner; K Böker; S Gloger; K J Oldhafer; M Behrend; P Flemming; M P Manns
Journal:  Digestion       Date:  1999 Nov-Dec       Impact factor: 3.216

3.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation).

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann
Journal:  Eur Heart J       Date:  2006-08       Impact factor: 29.983

4.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

5.  Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.

Authors:  Giancarlo Agnelli; Alexander Gallus; Samuel Z Goldhaber; Sylvia Haas; Menno V Huisman; Russel D Hull; Ajay K Kakkar; Frank Misselwitz; Sebastian Schellong
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

6.  Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure.

Authors:  Carl C Schimanski; Jürgen Burg; Markus Möhler; Thomas Höhler; Stephan Kanzler; Gerd Otto; Peter R Galle; Ansgar W Lohse
Journal:  J Hepatol       Date:  2004-07       Impact factor: 25.083

7.  Acenocoumarol is not a safe alternative for anticoagulation in phenprocoumon-induced hepatic failure. Report of two cases.

Authors:  Markus Neef; Zsuzsanna Kerekes; Hans-Peter Fischer; Tilman Sauerbruch; Ulrich Spengler
Journal:  Digestion       Date:  2003       Impact factor: 3.216

8.  [Phenprocoumon-induced cholestatic hepatitis].

Authors:  S Woolley; H R Burger; U Zellweger
Journal:  Dtsch Med Wochenschr       Date:  1995-11-03       Impact factor: 0.628

9.  Drug-induced hepatitis: a rare complication of oral anticoagulants.

Authors:  T Höhler; M Schnütgen; I Helmreich-Becker; W J Mayet; K H Mayer zum Büschenfelde
Journal:  J Hepatol       Date:  1994-09       Impact factor: 25.083

10.  Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.

Authors:  E Perzborn; D Kubitza; F Misselwitz
Journal:  Hamostaseologie       Date:  2007-09       Impact factor: 1.778

  10 in total
  2 in total

1.  [Role of vitamin K antagonists from a hepatologist's point of view].

Authors:  G Kneiseler; A Canbay; G Gerken
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

2.  Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments.

Authors:  Sven Schmiedl; Marietta Rottenkolber; Jacek Szymanski; Werner Siegmund; Marion Hippius; Katrin Farker; Bernd Drewelow; Joerg Hasford; Petra Thürmann
Journal:  Dtsch Arztebl Int       Date:  2013-04-05       Impact factor: 5.594

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.